Published in Cancer Weekly, December 9th, 1996
The application is based on the results of a Phase II clinical trial in 51 patients with advanced disease which was completed in 1993 under the supervision of Dr. Jaime de la Garza, National Cancer Institute. The results from that trial demonstrated that Virulizin provided patient benefit through improvements in survival and quality of life.
"We are very pleased to be taking this first step towards the commercialization of Virulizin," said...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.